Pharmaceutical Technology
August 01, 2008
Articles
2008 Supplement
3
The author outlines the opportunities and challenges for manufacturers aiming to enter the BRIC-country markets.
August 01, 2008
Articles
2008 Supplement
3
To meet the demands of early-stage development, contract research organizations can evaluate various dosage-form options. The author examines various methods of capsule filling, including binary blends.
August 01, 2008
Articles
2008 Supplement
3
J. Scott Tarrant, executive vice-president of Xceleron, explains the role of microdosing in drug development. He describes how microdose data can be used to predict pharmacological dose absorption, distribution, metabolism, and excretion/pharmacokinetic outcomes using accelerator mass spectrometry.
August 01, 2008
Articles
2008 Supplement
3
Gonghua Pan, associate director and head of the parallel medicinal chemistry sourcing operations at Pfizer, explains the evolution of the company's approach to outsourcing research and development from a line-or function-centric approach to an integrated sourcing model. This analysis includes the role that contract research organizations in Asia play in the company's outsourcing actvities.
August 01, 2008
Articles
2008 Supplement
3
A sponsor company must investigate the manufacturing automation and systems, laboratory automation and systems, information-technology infrastructure, and business applications of each potential contract manufacturing organization.
August 01, 2008
Articles
2008 Supplement
3
Survey results indicate a healthy market, but increasing competition.
August 01, 2008
Articles
2008 Supplement
3
Outsourcing strategies of large pharma companies are changing. The CEO of Patheon talks about his company's plan to meet customers' changing needs.
August 01, 2008
Articles
2008 Supplement
3
As pharma companies outsource new types of projects, contractors are trying to meet new needs.
August 01, 2008
Articles
2008 Supplement
3
The high-profile case of contaminated heparin from a Chinese supplier has intensified the debate on the effectiveness of FDA's process for inspecting foreign drug-manufacturing facilities. The article examines proposed legislative and regulatory reforms and actions taken by the agency to improve drug-import safety.